8-K: Lisata Therapeutics Secures Foundational Certepetide Patent, Extending Market Exclusivity to 2040

Lisata Therapeutics announced the issuance of a new U.S. composition of matter patent for its investigational drug certepetide, providing exclusive rights and extending intellectual property protection until March 2040.

Summary

• Lisata Therapeutics, Inc. has been issued U.S. Patent No. 12,351,653 by the United States Patent and Trademark Office (USPTO) for certepetide.
• The patent covers the composition of matter of certepetide, including its chemical structure, pharmacokinetic properties, methods of manufacturing, and applications for treating solid tumor cancers.
• This patent provides the strongest form of intellectual property protection, granting exclusive rights to the drug and preventing others from manufacturing or selling it.
• The patent is set to expire in March 2040, with a subsequent opportunity for patent term extension.
• Certepetide (formerly LSTA1) is a cyclic peptide product candidate designed to activate a novel uptake pathway, allowing co-administered anti-cancer drugs to more effectively target and penetrate solid tumors.
• Certepetide has demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials for pancreatic cancer and is being explored for various solid tumors.
• The drug has received several designations, including Fast Track (U.S.), Orphan Drug Designation for pancreatic cancer (U.S. and E.U.), Orphan Drug Designation for glioma (U.S.), Orphan Drug Designation for osteosarcoma (U.S.), and Rare Pediatric Disease Designation for osteosarcoma (U.S.).
• The company projects its current capital will fund operations into the fourth quarter of 2026, covering anticipated data milestones from ongoing and planned clinical trials.

Sentiment

Score: 8

Explanation: The issuance of a composition of matter patent is a highly significant and positive event for a clinical-stage pharmaceutical company, providing strong intellectual property protection and a long period of market exclusivity for a key drug candidate. This significantly de-risks future commercialization and enhances partnership potential.

Positives

• Securing a composition of matter patent for certepetide provides the strongest form of intellectual property protection, granting exclusive rights to the drug.
• The patent extends IP protection for certepetide until March 2040, with potential for further extension, significantly delaying generic encroachment for nearly two decades.
• This extended patent protection enhances commercialization efforts by offering long-term market exclusivity.
• The patent strengthens Lisata's negotiating position with potential partners, increasing the potential for sustained growth and value creation for shareholders.
• Certepetide has already demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials for pancreatic cancer.
• The drug has received multiple valuable designations, including Fast Track, Orphan Drug Designations for pancreatic cancer, glioma, and osteosarcoma, and Rare Pediatric Disease Designation for osteosarcoma.
• Lisata's projected capital is expected to fund operations into the fourth quarter of 2026, encompassing anticipated data milestones.

Risks

• Results observed from preliminary data may not be indicative of final results, and clinical outcomes could materially change following more comprehensive reviews of the data and as more patient data becomes available.
• Product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• The safety and efficacy of Lisata's product candidates are subject to ongoing evaluation.
• Decisions of regulatory authorities and the timing thereof could impact development timelines.
• The duration and impact of regulatory delays in Lisata's clinical programs could affect the company's progress.
• Lisata's ability to finance its operations is a factor influencing its continued development.
• The likelihood and timing of the receipt of future milestone and licensing fees are uncertain.
• The future success of Lisata's scientific studies is not guaranteed.
• Lisata's ability to successfully develop and commercialize drug candidates is subject to various factors.
• The timing for starting and completing clinical trials is difficult to predict.
• Rapid technological change in Lisata's markets could impact its competitive position.
• Lisata's ability to protect its intellectual property rights, despite this new patent, remains a continuous risk.
• Legislative, regulatory, political, and economic developments could affect the company's operations and prospects.

Future Outlook

Lisata Therapeutics expects to announce numerous milestones over the next 1.5 years, including anticipated data milestones from its ongoing and planned clinical trials. The company projects that its current capital will fund operations into the fourth quarter of 2026. The newly issued patent is expected to aid commercialization efforts by offering long-term market exclusivity and enhancing the potential for future development and commercialization of certepetide, strengthening negotiating positions with potential partners, and increasing the potential for sustained growth and value creation for shareholders.

Management Comments

• "Securing this patent is profoundly significant as it not only strengthens Lisatas robust IP estate, but, more importantly, grants exclusive rights to the drug itself, preventing others from manufacturing or selling it."
• "This new patent marks a key milestone, significantly boosting the value of both certepetide and the Company by delaying generic encroachment for essentially the next two decades."
• "This extended patent protection aids our commercialization efforts by offering long-term market exclusivity and enhances the potential future development and commercialization of certepetide."
• "It not only secures our IP but also greatly strengthens our negotiating position with potential partners, increasing the potential for sustained growth and value creation for our shareholders."

Industry Context

The pharmaceutical industry, particularly in oncology, relies heavily on strong intellectual property protection to justify the significant investment in research and development. A composition of matter patent, as secured by Lisata for certepetide, is considered the strongest form of IP, providing a competitive moat against generic competition for an extended period. This patent positions Lisata more favorably in the competitive landscape of solid tumor therapies, potentially attracting more robust partnerships and investment, aligning with the industry trend of valuing novel mechanisms of action and long-term market exclusivity.

Comparison to Industry Standards

• The issuance of a composition of matter patent is a standard and highly desirable achievement for a clinical-stage pharmaceutical company, as it provides the broadest and strongest form of intellectual property protection for a drug candidate. This is comparable to foundational patents held by major pharmaceutical companies for their blockbuster drugs, such as Pfizer's Lipitor (atorvastatin) or Merck's Keytruda (pembrolizumab), which secure market exclusivity for decades.
• The patent term extending to March 2040, with potential for further extension, provides a long runway for commercialization, which is critical for recouping R&D costs and generating significant revenue, similar to the long patent lives sought by companies like Gilead Sciences for its antiviral drugs or Regeneron for its antibody therapies.
• The multiple designations received by certepetide (Fast Track, Orphan Drug, Rare Pediatric Disease) are indicative of its potential to address unmet medical needs, a strategy often pursued by biotech companies to accelerate development and gain market advantages, akin to how companies like Sarepta Therapeutics have leveraged such designations for rare disease therapies.

Stakeholder Impact

• Shareholders: The patent grant is highly positive, securing long-term market exclusivity for a key asset, potentially increasing the value of certepetide and the company, and strengthening future growth and value creation.
• Patients: The continued development and potential commercialization of certepetide, aided by this patent, could lead to more effective treatments for advanced solid tumors and other serious diseases.
• Potential Partners: The strengthened intellectual property position makes Lisata a more attractive partner for collaborations, potentially leading to new commercial and R&D partnerships.
• Competitors: The exclusive rights granted by the composition of matter patent will prevent competitors from manufacturing or selling certepetide, delaying generic encroachment for an extended period.

Next Steps

• Announce numerous milestones over the next 1.5 years.
• Continue ongoing and planned clinical trials for certepetide.
• Anticipate data milestones from clinical trials.
• Explore potential partnerships for certepetide.

Key Dates

Recommendation

Keywords

Certepetide, Patent, Intellectual Property, Solid Tumors, Oncology, Pharmaceutical, Biotechnology, Clinical Stage, Drug Development, Composition of Matter, LSTA, Lisata Therapeutics, Pancreatic Cancer, Orphan Drug, Fast Track, USPTO